Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
How naloxone saves lives in opioid overdose
| How naloxone saves lives in opioid overdose |
| Pubbl/distr/stampa | [Bethesda, Md.] : , : NIH, U.S. National Library of Medicine, , 2019 |
| Descrizione fisica | 1 online resource (1 video file (5 min., 39 sec.)) : sound, color |
| Soggetto topico |
Opioids - Overdose
Naloxone - Therapeutic use Opioid abuse - Treatment Pain - Alternative treatment |
| Soggetto genere / forma |
Internet videos.
Video recordings. |
| Formato | Videoregistrazioni  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | MedlinePlus: trusted health information for you |
| Record Nr. | UNINA-9910713783203321 |
| [Bethesda, Md.] : , : NIH, U.S. National Library of Medicine, , 2019 | ||
| Videoregistrazioni | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nonclinical assessment of abuse potential for new pharmaceuticals / / edited by Carrie G. Markgraf, Thomas J. Hudzik and David R. Compton
| Nonclinical assessment of abuse potential for new pharmaceuticals / / edited by Carrie G. Markgraf, Thomas J. Hudzik and David R. Compton |
| Pubbl/distr/stampa | London, [England] ; ; San Diego, California : , : Academic Press, an imprint of Elsevier, , 2015 |
| Descrizione fisica | 1 online resource (321 p.) |
| Disciplina | 362.29 |
| Soggetto topico |
Drug abuse
Drugs - Overdose Opioids - Overdose |
| ISBN |
0-12-420216-0
0-12-420172-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Nonclinical Assessment of Abuse Potential for New Pharmaceuticals; Copyright; CONTENTS; CONTRIBUTORS; FOREWORD; PREFACE; ACKNOWLEDGMENTS; Chapter 1 - Nonclinical Assessment of Abuse Potential for New Pharmaceuticals in a Regulatory Space; 1. TERMINOLOGY; 2. ANIMAL MODELS OF ABUSE POTENTIAL; 3. REGULATION OF DRUGS OF ABUSE; 4. SCHEDULING; 5. SUMMARY; REFERENCES; Chapter 2 - Neurochemistry of Abuse Liability Assessment and Primary Behavioral Correlates; 1. INTRODUCTION; 2. REWARD SYSTEM; REFERENCES; Chapter 3 - Rat Self-Administration; 1. INTRODUCTION; 2. REGULATORY ISSUES
3. THE OPERANT CHAMBER SET UP4. THE TRAINING; 5. THE DRUG CONTINGENCIES; 6. THE TESTING; 7. DOSE-RESPONSE RELATIONSHIPS; 8. MAINTENANCE DRUG; 9. GENDER; 10. LIMITED VERSUS UNLIMITED ACCESS TO DRUG DURING TRAINING; 11. RESPONSE TOPOGRAPHY; 12. REINFORCING EFFICACY; 13. CONCLUSION; REFERENCES; Chapter 4 - Nonhuman Primate Self-Administration in Assessments of Abuse Potential; 1. ASSESSMENT OF ABUSE POTENTIAL IN LABORATORY ANIMALS; 2. RATIONALE FOR USING NONHUMAN PRIMATES IN ASSESSMENTS OF ABUSE POTENTIAL; 3. STUDYING DRUG SELF-ADMINISTRATION IN NONHUMAN PRIMATES 4. STUDYING DRUG DEPENDENCE IN NONHUMAN PRIMATES5. CONCLUSIONS AND RECOMMENDATIONS; ACKNOWLEDGMENTS; REFERENCES; Chapter 5 - Assessing Physical Dependence; 1. INTRODUCTION; 2. DEFINITIONS; 3. NEUROBIOLOGY OF WITHDRAWAL; 4. WITHDRAWAL: PRECIPITATED AND NONPRECIPITATED; 5. USE OF POSITIVE AND NEGATIVE CONTROLS IN THE WITHDRAWAL TEST; 6. ANIMAL MODEL OF NONPRECIPITATED WITHDRAWAL; 7. GENERAL CONSIDERATIONS; 8. GOOD LABORATORY PRACTICES; 9. REGULATORY GUIDANCE AND GLOBAL REGULATORY FRAMEWORK; 10. TIMELINES; 11. PHYSICAL DEPENDENCE TESTING OF LARGE MOLECULES 12. PHYSICAL DEPENDENCE TESTING IN HUMANS13. CONCLUSIONS; LIST OF ABBREVIATIONS; REFERENCES; Chapter 6 - Drug Discrimination: Use in Preclinical Assessment of Abuse Liability; 1. FROM STATE DEPENDENCY TO DRUG DISCRIMINATION: A BRIEF HISTORY; 2. METHODOLOGY; 3. SOFTWARE; 4. TRAINING DRUGS; 5. DRUG DISCRIMINATION: TRAINING AND TESTING; 6. DATA INTERPRETATION: LEVELS OF GENERALIZATION; 7. THE DISCRIMINATIVE EFFECT; 8. TIME COURSE DETERMINATION; 9. PHARMACOKINETICS; 10. STRATEGIC PLACEMENT OF DRUG DISCRIMINATION IN THE ABUSE LIABILITY ASSESSMENT TOOLBOX 11. DRUG DISCOVERY AND DEVELOPMENT STRATEGIC USE OF DRUG DISCRIMINATIONREFERENCES; Chapter 7 - Conditioned Place Preference as a Preclinical Model for Screening Pharmacotherapies for Drug Abuse; 1. INTRODUCTION; 2. BASIC PRINCIPLES OF CONDITIONED PLACE PREFERENCE; 3. APPLICATION OF CONDITIONED PLACE PREFERENCE TO MEDICATION DEVELOPMENT; 4. RECENT FINDINGS; 5. CONCLUSION; REFERENCES; Chapter 8 - Utility of Intracranial Self-Stimulation in the Assessment of the Abuse Liability of New Pharmaceuticals; 1. INTRODUCTION |
| Record Nr. | UNINA-9910797349903321 |
| London, [England] ; ; San Diego, California : , : Academic Press, an imprint of Elsevier, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nonclinical assessment of abuse potential for new pharmaceuticals / / edited by Carrie G. Markgraf, Thomas J. Hudzik and David R. Compton
| Nonclinical assessment of abuse potential for new pharmaceuticals / / edited by Carrie G. Markgraf, Thomas J. Hudzik and David R. Compton |
| Pubbl/distr/stampa | London, [England] ; ; San Diego, California : , : Academic Press, an imprint of Elsevier, , 2015 |
| Descrizione fisica | 1 online resource (321 p.) |
| Disciplina | 362.29 |
| Soggetto topico |
Drug abuse
Drugs - Overdose Opioids - Overdose |
| ISBN |
0-12-420216-0
0-12-420172-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Nonclinical Assessment of Abuse Potential for New Pharmaceuticals; Copyright; CONTENTS; CONTRIBUTORS; FOREWORD; PREFACE; ACKNOWLEDGMENTS; Chapter 1 - Nonclinical Assessment of Abuse Potential for New Pharmaceuticals in a Regulatory Space; 1. TERMINOLOGY; 2. ANIMAL MODELS OF ABUSE POTENTIAL; 3. REGULATION OF DRUGS OF ABUSE; 4. SCHEDULING; 5. SUMMARY; REFERENCES; Chapter 2 - Neurochemistry of Abuse Liability Assessment and Primary Behavioral Correlates; 1. INTRODUCTION; 2. REWARD SYSTEM; REFERENCES; Chapter 3 - Rat Self-Administration; 1. INTRODUCTION; 2. REGULATORY ISSUES
3. THE OPERANT CHAMBER SET UP4. THE TRAINING; 5. THE DRUG CONTINGENCIES; 6. THE TESTING; 7. DOSE-RESPONSE RELATIONSHIPS; 8. MAINTENANCE DRUG; 9. GENDER; 10. LIMITED VERSUS UNLIMITED ACCESS TO DRUG DURING TRAINING; 11. RESPONSE TOPOGRAPHY; 12. REINFORCING EFFICACY; 13. CONCLUSION; REFERENCES; Chapter 4 - Nonhuman Primate Self-Administration in Assessments of Abuse Potential; 1. ASSESSMENT OF ABUSE POTENTIAL IN LABORATORY ANIMALS; 2. RATIONALE FOR USING NONHUMAN PRIMATES IN ASSESSMENTS OF ABUSE POTENTIAL; 3. STUDYING DRUG SELF-ADMINISTRATION IN NONHUMAN PRIMATES 4. STUDYING DRUG DEPENDENCE IN NONHUMAN PRIMATES5. CONCLUSIONS AND RECOMMENDATIONS; ACKNOWLEDGMENTS; REFERENCES; Chapter 5 - Assessing Physical Dependence; 1. INTRODUCTION; 2. DEFINITIONS; 3. NEUROBIOLOGY OF WITHDRAWAL; 4. WITHDRAWAL: PRECIPITATED AND NONPRECIPITATED; 5. USE OF POSITIVE AND NEGATIVE CONTROLS IN THE WITHDRAWAL TEST; 6. ANIMAL MODEL OF NONPRECIPITATED WITHDRAWAL; 7. GENERAL CONSIDERATIONS; 8. GOOD LABORATORY PRACTICES; 9. REGULATORY GUIDANCE AND GLOBAL REGULATORY FRAMEWORK; 10. TIMELINES; 11. PHYSICAL DEPENDENCE TESTING OF LARGE MOLECULES 12. PHYSICAL DEPENDENCE TESTING IN HUMANS13. CONCLUSIONS; LIST OF ABBREVIATIONS; REFERENCES; Chapter 6 - Drug Discrimination: Use in Preclinical Assessment of Abuse Liability; 1. FROM STATE DEPENDENCY TO DRUG DISCRIMINATION: A BRIEF HISTORY; 2. METHODOLOGY; 3. SOFTWARE; 4. TRAINING DRUGS; 5. DRUG DISCRIMINATION: TRAINING AND TESTING; 6. DATA INTERPRETATION: LEVELS OF GENERALIZATION; 7. THE DISCRIMINATIVE EFFECT; 8. TIME COURSE DETERMINATION; 9. PHARMACOKINETICS; 10. STRATEGIC PLACEMENT OF DRUG DISCRIMINATION IN THE ABUSE LIABILITY ASSESSMENT TOOLBOX 11. DRUG DISCOVERY AND DEVELOPMENT STRATEGIC USE OF DRUG DISCRIMINATIONREFERENCES; Chapter 7 - Conditioned Place Preference as a Preclinical Model for Screening Pharmacotherapies for Drug Abuse; 1. INTRODUCTION; 2. BASIC PRINCIPLES OF CONDITIONED PLACE PREFERENCE; 3. APPLICATION OF CONDITIONED PLACE PREFERENCE TO MEDICATION DEVELOPMENT; 4. RECENT FINDINGS; 5. CONCLUSION; REFERENCES; Chapter 8 - Utility of Intracranial Self-Stimulation in the Assessment of the Abuse Liability of New Pharmaceuticals; 1. INTRODUCTION |
| Record Nr. | UNINA-9910821051703321 |
| London, [England] ; ; San Diego, California : , : Academic Press, an imprint of Elsevier, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Treating overdose with Naloxone
| Treating overdose with Naloxone |
| Pubbl/distr/stampa | [Rockville, Md.] : , : Department of Health & Human Services- USA, Substance Abuse and Mental Health Services Administration |
| Descrizione fisica | 1 online resource (1 page) : color illustrations |
| Soggetto topico |
Naloxone
Opioids - Overdose Drugs - Overdose |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910713896403321 |
| [Rockville, Md.] : , : Department of Health & Human Services- USA, Substance Abuse and Mental Health Services Administration | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Opioids - Overdose
(4)
- Drugs - Overdose (3)
- Drug abuse (2)
- Naloxone (1)
- Naloxone - Therapeutic use (1)